Medincell Advances 3.11% in Session Despite Limited Volumes
Medincell advances 3.11% on Wednesday, January 14, 2026, at the opening, reaching 27.18 euros, amid limited trading volumes and anticipation of regulatory approval for Olanzapine LAI expected by the end of 2026. The company released its 2026 financial calendar on Sunday, with annual results anticipated on June 16.
Medincell's stock shows a gain of 3.11% on Wednesday, January 14, 2026, at the opening, settling at 27.18 euros compared to 26.36 euros at the previous day's close. This rebound occurs in a context of limited trading volumes, with only 0.05% of the capital traded, suggesting a technical progression without significant buying pressure. Over the week, the stock has accelerated with an increase of 11.12%, indicating a renewed interest since the beginning of the year. However, this upward dynamic contrasts with the quarterly performance, which still shows a decline of 18.18%, a sign of persistent volatility in the stock. The technical context is gradually improving. The Relative Strength Index (RSI) stands at 60, indicating a neutral to slightly bullish zone, without overbought signals. This level suggests that the stock is finding balance after a consolidation phase that began at the end of 2025. The price remains below the 50-day moving average, set at 28.09 euros, a key resistance threshold to cross for a sustained bullish breakout. Conversely, the stock is significantly above its 200-day moving average (21.17 euros), confirming a positive long-term trend.
Financial Calendar and Analyst Perspectives
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Medincell has published its financial calendar for 2026, with the presentation of the annual results for the fiscal year 2025-2026 scheduled for June 16, 2026, followed by the general meeting on September 10, 2026. Analyst recommendations reflect contrasting views on the stock's valuation. Jefferies maintains a buy recommendation with a target price of 50 euros, representing an upside potential of 84% compared to the current price. Conversely, TP Icap Midcap has downgraded its recommendation to hold with a target at 32 euros, indicating caution after the stock's strong appreciation over the past year, which still shows a gain of 66.75%. The MACD histogram, at 0.24, confirms a slight bullish momentum in the short term, but remains to be monitored to validate a continuation of the trend.
We are pleased with the company’s growth and momentum.
Total income €14,1 million; Revenues €11,6 million (+35 %); UZEDY® royalties €4,2 million; Operating result €(6,6) million (improved 13 % year-over-year); Net result €(16 078) thousand; Cash and low-risk financial investments €53,5 million (incl. €49,8 million cash and €3,7 million low-risk investments); Net financial debt €17 629 thousand; NDA for Olanzapine LAI submitted to FDA on December 9, 2025; AbbVie partnership advancing with regulatory package expected in 2026.
Risks mentioned
Foreign exchange risk: weakness of USD vs EUR impacted revenues and generated ~€1 million FX losses
Dependency on partner commercialization (Teva) for UZEDY® royalties and sales forecasts
Regulatory risk: approvals (e.g., Olanzapine LAI) and acceptance for review uncertain
Financial volatility linked to fair value revaluation of EIB BSA warrants (non-cash €6,8 million impact)
Opportunities identified
Olanzapine LAI: NDA submitted and potential launch could be a major growth catalyst
UZEDY®: upward revision of 2025 net sales forecast by Teva (from $160 million to $190-200 million)
AbbVie partnership: first program advancing toward first-in-human trials (regulatory package expected 2026)
Gates Foundation financing: new $3 million envelope to advance mdc-STM malaria program
Expanded geographic approvals (Canada, South Korea) supporting broader commercialization
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
